Skip to main content

This job has expired

You will need to login before you can apply for a job.

Scientist, Screening Methods and Process Development (AEGIS)

Employer
Intellia Therapeutics
Location
Cambridge, MA
Start date
Sep 17, 2021

View more

Job Details

Why Join Intellia? 

Our mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. 

Beyond our science, we live our four core values: One, Explore, Disrupt, Deliver and feel strongly that you can achieve more at Intellia. We have a single-minded determination to excel and succeed together. We believe in the power of curiosity and pushing boundaries. We welcome challenging thoughts and imagination to develop innovative solutions. And we know that patients are counting on us to make the promise a reality, so we must maintain high standards and get it done. 

We want all of our people to go beyond what is possible. We aren’t constrained by typical end rails, and we aren’t out to just “treat” people. We’re all in this for something more. We’re driven to cure and motivated for change. Just imagine the possibilities of what we can do together.   

How you will Achieve More with Intellia:

As a Scientist in the Screening Team, you will work with a cross-functional team, building and refining screening methods to meet the needs of our growing therapeutic landscape. You will spearhead the development of novel high-throughput genetic perturbation methods to enable the advancement of emerging technologies. By applying your skills in primary, immortalized and iPSC-derived cell culture, you will become the subject matter expert in genetic perturbation methods for current and emerging therapeutic targets and a broad spectrum of CRISPR technologies. Your efforts will touch all parts of the organization, from research and development to legal and technical operations. Methods and data generated by you will be at the forefront of the next therapeutic or technological advancement. As a Screening Team Scientist, you will:

  • Design, execute and troubleshoot high-throughput CRISPR screens in T-cell, primary, and immortalized cells with the application of a variety of genetic perturbation methods

  • Have hands-on proficiency with sample preparation for Next-generation sequencing and knowledge of downstream analysis

  • Develop methods and perform experiments to measure mRNA and/or protein expression via RT-PCR, FACS, ELISA, MSD, ddPCR

  • Provide key input to stakeholders to advance future therapies and technologies

About You:

We are in search of driven and high-energy candidates with a Ph.D. in Cell Biology, Molecular Biology, Immunology, or a related field with 0-2 years of post-PhD experience. Strong candidates with Bachelors (6-8 years) or Masters (4-6 years) in related disciplines will also be considered. The ideal candidate has extensive knowledge of CRISPR and experience leveraging high-throughput liquid handling automation in the development, optimization, and validation of bioassays. Additional role requirements include:

  • Strong data analysis, interpretation, visualization, and presentation skills

  • Clear and timely communication and documentation of results in electronic lab notebooks

  • Organizational proficiency and ability to plan multiple concurrent workflows

  • Experience and desire to mentor team members by sharing your expertise in experimental design, execution, troubleshooting, and interpretation

If you are a passionate, curious, and driven team player, we encourage you to apply. 

Meet your future team:

You will be joining our Screening Team; a group of motivated, dedicated, and highly collaborative scientists who are driven to change patients’ lives. The Screening Team is part of the multifunctional platform group, AEGIS (Automation, Engineering, Genomics, Informatics, Screening) where you will report directly to the Associate Director, Screening. As we build our team, we’re excited to work with people who share our commitment and energy to making a difference.

We are currently working mostly on-site to execute our experiments in a wet-lab environment. Therefore, we require a candidate to be currently local to Cambridge MA, or open to relocating. While much of the day-to-day operations require wet-lab work, our team is focused on building not just technical expertise but fostering an environment for the growth of scientists interested in a career in therapeutic biotechnology. If you join our team, you can expect to join a fast, exciting, and collaborative environment. We look forward to fostering your skills, learning from your experiences, and building a larger team together. We are just getting started.

#LI-DG1

EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.

Company

Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
 
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
 
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Change life stories with genome editing therapies!

Stock Symbol: NTLA

TwitterInstagram

Company info
Website
Phone
(857) 285-6200
Location
40 Erie Street
Cambridge
Massachusetts
02139
United States

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert